This Article Full Text Full Text (PDF) Correction (v118,pe132) All Versions of this Article: 116/21/2420    most recent CIRCULATIONAHA.107.697763v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Feng, D. Articles by Klarich, K. W. Search for Related Content PubMed PubMed Citation Articles by Feng, D. Articles by Klarich, K. W. Pubmed/NCBI databases Medline Plus Health Information Heart Disease in Women Heart Diseases Related Collections Myocardial cardiomyopathy disease Coagulation Thrombosis risk factors Echocardiography Embolic stroke

(Circulation. 2007;116:2420-2426.)
© 2007 American Heart Association, Inc.

Vascular Medicine

Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis

DaLi Feng, MD; William D. Edwards, MD; Jae K. Oh, MD; Krishnaswamy Chandrasekaran, MD; Martha Grogan, MD; Matthew W. Martinez, MD; Imran I. Syed, MD; Deborah A. Hughes, MD; John A. Lust, MD; Allan S. Jaffe, MD; Morie A. Gertz, MD; Kyle W. Klarich, MD

From the Mayo Clinic College of Medicine (D.F., M.W.M., I.I.S., D.A.H.) and the Divisions of Cardiovascular Diseases (D.F., J.K.O., K.C., M.G., M.W.M., I.I.S., D.A.H., A.S.J., K.W.K.), Anatomic Pathology (W.D.E.), and Hematology (J.A.L., M.A.G.), Mayo Clinic, Rochester, Minn.

Correspondence to Kyle W. Klarich, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail klarich.kyle{at}mayo.edu

Received February 21, 2007; accepted August 31, 2007.

Background— Patients with primary amyloidosis (AL type) have a poor prognosis, in part due to frequent cardiac involvement. Although intracardiac thrombus has been reported in anecdotal cases, neither its frequency nor its role in causing mortality is known. Furthermore, the clinical and echocardiographic variables that may be associated with thromboembolism in cardiac amyloidosis have not been defined.

Methods and Results— A total of 116 autopsy or explanted cases of cardiac amyloidosis (55 AL and 61 other type) were identified in the Mayo Clinic. Forty-six fatal nonamyloid trauma cases served as controls. Each heart was examined for intracardiac thrombus. The cause of death was determined from autopsy and clinical notes. Intracardiac thrombosis was identified in 38 hearts (33%). Twenty-three had 1 thrombus, whereas 15 had 2 to 5 thrombi. Although subjects in the AL group were younger and had less atrial fibrillation than those with other types of amyloidosis, the AL group had significantly more intracardiac thrombus (51% versus 16%, P<0.001) and more fatal embolic events (26% versus 8%, P<0.03). Control hearts had no intracardiac thrombus. The presence of both atrial fibrillation and AL was associated with an extremely high risk for thromboembolism (odds ratio 55.0 [95% confidence interval 8.1 to 1131.4]). By multivariate analysis, AL type (odds ratio 8.4 [95% confidence interval 1.8 to 51.2]) and left ventricular diastolic dysfunction (odds ratio 12.2 [95% confidence interval 2.7 to 72.7]) were independently associated with thromboembolism.

Conclusions— A high frequency of intracardiac thrombosis was present in cardiac amyloidosis. Furthermore, thromboembolism caused significant fatality. Several risk factors for thromboembolism were identified. Early screening, especially in high-risk patients, and early anticoagulation might reduce morbidity and mortality.

---

 

CLINICAL PERSPECTIVE